论文部分内容阅读
越来越多的资料表明，高甘油三酯血症是冠心病的重要危险因素，它主要与血浆致动脉粥样硬化的富含甘油三酯脂蛋白（ＴＲＬ）的增加有关。近年来的多项临床试验显示，他汀类调脂药物能有效降低高甘油三酯血症患者血浆中ＴＲＬ浓度，减少血浆甘油三酯水平，降低冠心病的发生率。本文概述了他汀类调脂药降低血浆甘油三酯的机理，及其治疗高甘油三酯血症的临床研究进展。
More and more data indicate that hypertriglyceridemia is an important risk factor for coronary heart disease, which is mainly related to the increase of plasma triglyceride-rich triglyceride (TRL). In recent years, a number of clinical trials show that statin lipid-lowering drugs can effectively reduce the plasma TRL concentration in patients with hypertriglyceridemia, reduce plasma triglyceride levels and reduce the incidence of coronary heart disease. This article provides an overview of the mechanism by which statins lipid-lowering drugs lower plasma triglycerides and its clinical progress in the treatment of hypertriglyceridemia.